Peterson Wealth Services Purchases 353 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Peterson Wealth Services increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,616 shares of the medical research company’s stock after buying an additional 353 shares during the quarter. Thermo Fisher Scientific accounts for about 1.5% of Peterson Wealth Services’ portfolio, making the stock its 21st biggest holding. Peterson Wealth Services’ holdings in Thermo Fisher Scientific were worth $3,512,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Moneta Group Investment Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 104,536.8% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock valued at $4,601,150,000 after buying an additional 8,347,260 shares during the last quarter. Providence Capital Advisors LLC lifted its holdings in Thermo Fisher Scientific by 61,754.7% during the 1st quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company’s stock worth $10,136,000 after purchasing an additional 5,832,730 shares during the last quarter. Norges Bank acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $3,105,677,000. Morgan Stanley lifted its holdings in Thermo Fisher Scientific by 17.7% during the 4th quarter. Morgan Stanley now owns 11,730,063 shares of the medical research company’s stock worth $6,459,629,000 after purchasing an additional 1,764,312 shares during the last quarter. Finally, International Assets Investment Management LLC lifted its holdings in Thermo Fisher Scientific by 61,995.4% during the 4th quarter. International Assets Investment Management LLC now owns 1,009,671 shares of the medical research company’s stock worth $535,923,000 after purchasing an additional 1,008,045 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now directly owns 49,155 shares in the company, valued at $27,311,992.65. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock valued at $28,513,384 in the last ninety days. 0.32% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Down 1.1 %

TMO traded down $6.17 during midday trading on Thursday, hitting $541.08. 729,874 shares of the company were exchanged, compared to its average volume of 1,527,658. The firm has a market capitalization of $206.54 billion, a P/E ratio of 35.42, a P/E/G ratio of 2.33 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The firm’s 50 day moving average price is $571.57 and its 200-day moving average price is $527.01. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. The company had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm’s revenue was down 4.9% compared to the same quarter last year. During the same period in the previous year, the business earned $5.40 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 10.10%.

Analyst Upgrades and Downgrades

TMO has been the subject of several research reports. Evercore ISI lifted their price target on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. HSBC lifted their price objective on Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a report on Wednesday. Barclays cut Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Finally, Citigroup initiated coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $604.69.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.